ArticleObstetrics and gynecology2010
Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy.
Article in Obstetrics and gynecology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Endometrial hyperplasia as a risk factor of endometrial cancer.Archives of gynecology and obstetrics · 2022Pooled it
- Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis.PloS one · 2020Pooled it
- Management of Patients Diagnosed with Endometrial Hyperplasia: Comparison of Guidelines.Cancers · 2026Review
- Review
- Safety of hormonal IUD in breast cancer patients.European journal of obstetrics & gynecology and reproductive biology: X · 2025Article
- Article
- Diagnostic Efficiency of Endometrial Sampling Methods and Risk Factors for Endometrial Carcinoma and Precursor Lesions in Premenopausal Women.Journal of clinical medicine · 2025Article
- Few-shot learning to identify atypical endometrial hyperplasia and endometrial cancer based on transvaginal ultrasonic images.Heliyon · 2024Article
- Article
- Spectroscopic evaluation of carcinogenesis in endometrial cancer.Scientific reports · 2021Article
- Association of endometrial hyperplasia and cancer with a history of gestational diabetes.Cancer causes & control : CCC · 2017Article
- Therapeutic options for management of endometrial hyperplasia.Journal of gynecologic oncology · 2016Review
- Feasibility of RNA and DNA extraction from fresh pipelle and archival endometrial tissues for use in gene expression and SNP arrays.Obstetrics and gynecology international · 2013Article
- Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.American journal of obstetrics and gynecology · 2012Article
- Levonorgestrel-releasing intrauterine system treatment for endometrial hyperplasia and early endometrial cancer: a systematic review.Therapeutic advances in reproductive healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
objectiveLimited data exist to inform clinicians and patients as to the likelihood of long-term endometrial hyperplasia response to progestin therapy, especially for atypical hyperplasia. We evaluated women with complex and atypical endometrial hyperplasia, comparing those prescribed progestin with those not prescribed progestin.
methodsThis retrospective cohort study was conducted in 1985-2005 among women aged 18-88 years at an integrated health plan in Washington State. Women were ineligible if they achieved an outcome (endometrial carcinoma, hysterectomy, or both) within 8 weeks of hyperplasia diagnosis. Exposure was progestin use for at least 14 days by duration and recency. Outcomes included rate of 1) endometrial carcinoma, 2) hysterectomy, or 3) both. Analyses performed included Kaplan-Meier, incident rate ratios, and Cox proportional hazard ratios.
resultsOne thousand four hundred forty-three eligible women were identified. One thousand two hundred one had complex (n=164 no progestin) and 242 had atypical (n=62 no progestin) hyperplasia. During follow-up, a median of 5.3 years (range 8 weeks to 20.8 years), 71 women were diagnosed with endometrial carcinoma (35 complex, 36 atypia) and 323 underwent hysterectomy (216 complex, 107 atypia). Among women with complex and atypical hyperplasia, rates of endometrial carcinoma among progestin users were 3.6 and 20.5 per 1,000 woman-years, respectively (compared with women who did not use progestin, 10.8 and 101.4). Among women with complex and atypical hyperplasia, rates of hysterectomy among progestin users were 23.3 and 61.4 per 1,000 woman-years, respectively (compared with women who did not use progestin, 55.1 and 297.3).
conclusionEndometrial carcinoma risk is diminished approximately threefold to fivefold in women diagnosed with complex or atypical endometrial hyperplasia and dispensed progestin; hysterectomy risk is also decreased. LEVEL OF EVIDENCE: II.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.